公开(公告)号：US20110092479A1

公开(公告)日：2011-04-21

申请号：US12920050

申请日：2009-02-27

申请人： Kateri A. Ahrendt ,  Alexandre J. Buckmelter ,  Jason De Meese ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  Paul Lunghofer ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Jeongbeob Seo ,  Hongqi Tian ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

发明人： Kateri A. Ahrendt ,  Alexandre J. Buckmelter ,  Jason De Meese ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  Paul Lunghofer ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Jeongbeob Seo ,  Hongqi Tian ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

IPC分类号： A61K31/437 ,  C07D471/04 ,  A61K31/5377 ,  A61K31/496 ,  A61P35/00 ,  A61P35/02 ,  A61P13/12

CPC分类号： C07D471/04 ,  C07C311/08

摘要： Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

摘要翻译： 式I化合物可用于抑制Raf激酶。 公开了使用式I化合物和立体异构体，互变异构体，前药和其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US08338452B2

公开(公告)日：2012-12-25

申请号：US12920045

申请日：2009-02-27

申请人： Kateri A. Ahrendt ,  Alexandre J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

发明人： Kateri A. Ahrendt ,  Alexandre J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

IPC分类号： A01N43/42 ,  A61K31/44 ,  C07D471/02 ,  C07D491/02

CPC分类号： C07D471/04 ,  C07C311/08

摘要： Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

摘要翻译： 式（I）的化合物可用于抑制Raf激酶。 公开了使用式（I）化合物及其立体异构体，互变异构体，前药和其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20110110889A1

公开(公告)日：2011-05-12

申请号：US12920045

申请日：2009-02-27

申请人： Kateri A. Ahrendt et al. ,  Alexander J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

发明人： Kateri A. Ahrendt et al. ,  Alexander J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen R. Laird ,  David Moreno ,  Brad Newhouse ,  Li Ren ,  Steven M. Wenglowsky ,  Bainian Feng ,  Janet Gunzner ,  Kim Malesky ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Wendy B. Young

IPC分类号： A61K38/21 ,  C07D471/04 ,  C07D401/10 ,  C07D401/02 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/497 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07D471/04 ,  C07C311/08

摘要： Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

摘要翻译： 式（I）的化合物可用于抑制Raf激酶。 公开了使用式（I）化合物及其立体异构体，互变异构体，前药和其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20090111982A1

公开(公告)日：2009-04-30

申请号：US12341517

申请日：2008-12-22

申请人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

发明人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

IPC分类号： C07D487/04 ,  C07D401/12 ,  C07D403/02

CPC分类号： C07K5/0804

摘要： The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

公开(公告)号：US07491794B2

公开(公告)日：2009-02-17

申请号：US11093884

申请日：2005-03-29

申请人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  Yutong Jiang ,  April L. Kennedy ,  Peter J. Stengel ,  Steven M. Wenglowsky

发明人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  Yutong Jiang ,  April L. Kennedy ,  Peter J. Stengel ,  Steven M. Wenglowsky

IPC分类号： A61K38/12

CPC分类号： C07K5/0804

摘要： The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

摘要翻译： 实施方案提供了通式I-XIX的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

公开(公告)号：US20090111969A1

公开(公告)日：2009-04-30

申请号：US12341683

申请日：2008-12-22

申请人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

发明人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

IPC分类号： C07K5/00

CPC分类号： C07K5/0804

摘要： The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

公开(公告)号：US20090105471A1

公开(公告)日：2009-04-23

申请号：US12341971

申请日：2008-12-22

申请人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

发明人： Lawrence M. Blatt ,  Steven W. Andrews ,  Kevin R. Condroski ,  George A. Doherty ,  Yutong Jiang ,  John A. Josey ,  April L. Kennedy ,  Machender R. Madduru ,  Peter J. Stengel ,  Steven M. Wenglowsky ,  Benjamin T. Woodard ,  Laura Woodard

IPC分类号： C07D225/04 ,  C07D245/04

CPC分类号： C07K5/0804

摘要： The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.